Valproic acid. Review of a new antiepileptic drug.
Valproic acid is a new antiepileptic drug. It has a marked effect on generalized spike-wave discharges. The exact mechanism of action is uncertain; however, some evidence suggests an effect on the metabolism of gamma-aminobutyric acid. It is rapidly absorbed from the gastrointestinal (GI) tract. Concurrent administration with phenobarbital may result in elevated phenobarbital plasma concentrations. Administration with phenytoin sodium may transiently result in lower total phenytoin plasma levels. Side effects are generally mild and include fatigue, GI disturbances, weight gain, a fine postural and resting tremor, mild thrombocytopenia, and an increase in hepatic enzymes. Platelet counts and liver function monitoring should be done during valproic acid therapy. Drowsiness may be seen in patients receiving other antiepileptic drugs concurrently.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D004347:Drug Interactions; D004558:Electric Stimulation; D004569:Electroencephalography; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D051379:Mice; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D012640:Seizures / Q000517:prevention & control; D012894:Sleep Stages; D014635:Valproic Acid / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital